(Q34951790)

5 August 2017

1 reference

title

Molecular staging of lung and esophageal cancer (English)

1 reference

5 August 2017

Christine L Lau

1

1 reference

5 August 2017

Mary-Beth H Moore

2

1 reference

5 August 2017

Kelly R Brooks

3

1 reference

5 August 2017

Thomas A D'Amico

4

1 reference

5 August 2017

David H Harpole

5

1 reference

5 August 2017

publication date

1 June 2002

1 reference

Surgical Clinics of North America

5 August 2017

published in

1 reference

5 August 2017

volume

82

1 reference

5 August 2017

issue

3

1 reference

5 August 2017

page(s)

497-523

1 reference

Specific Association of Human Telomerase Activity with Immortal Cells and Cancer

5 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Prognostic significance of the expression ofras oncogene product in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Prognostic value of K-ras mutations, ras oncoprotein, and c-erb B-2 oncoprotein expression in adenocarcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

K-ras codon 12 mutations in Barrett's oesophagus and adenocarcinomas of the oesophagus and oesophagogastric junction

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

A comparison of epidermal growth factor receptor levels and other prognostic parameters in non-small cell lung cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Do molecular markers predict survival in non-small-cell lung cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Immunocytochemical markers in stage I lung cancer: relevance to prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

A biologic risk model for stage I lung cancer: immunohistochemical analysis of 408 patients with the use of ten molecular markers

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Angiogenesis and molecular biologic substaging in patients with stage I non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Immunohistochemical detection of p53 and c-erbB-2 in oesophageal carcinoma; no correlation with prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Tumor marker expression is predictive of survival in patients with esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Thymocyte apoptosis induced by p53-dependent and independent pathways.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

High affinity insertion/deletion lesion binding by p53. Evidence for a role of the p53 central domain

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Prognostic markers in resectable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Prognostic significance of p53 and ras p21 expression in nonsmall cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Mutations of the p53 Gene as a Predictor of Poor Prognosis in Patients With Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

The relationship of p53 immunostaining to survival in carcinoma of the lung

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Immunohistochemical detection of P53 protein is not associated with a poor prognosis in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Nuclear p53 overexpression is an independent prognostic parameter in node-negative non-small cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

p53 alterations in oesophageal cancer: association with clinicopathological features, risk factors, and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

p53 protein accumulation and p53 gene mutation in esophageal carcinoma. A molecular and immunohistochemical study with clinicopathologic correlations.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Anti-p53 antibodies in patients with Barrett's esophagus or esophageal carcinoma can predate cancer diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Expression of p53, PCNA, and C-erbB-2 in Barrett's metaplasia and adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

p53 Protein accumulation is a specific marker of malignant potential in Barrett's metaplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Potential application of p53 as an intermediate biomarker in Barrett's esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

p53 protein expression and prognosis in squamous cell carcinoma of the esophagus

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Clinical significance of p53, nm23, and bcl-2 in T3-4N1M0 oesophageal carcinoma: an immunohistochemical approach

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

bcl-x, a bcl-2-related gene that functions as a dominant regulator of apoptotic cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

bcl-2 protein in non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Bcl-X expression in esophageal squamous cell carcinoma: association with tumor progression and prognosis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Clinicopathologic significance of telomerase activity and hTERT mRNA expression in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Telomerase activity in esophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Telomerase reverse transcriptase expression is increased early in the Barrett's metaplasia, dysplasia, adenocarcinoma sequence

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Prognostic significance of the proliferation index in surgically resected non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Stage I nonsmall cell lung cancer. A multivariate analysis of treatment methods and patterns of recurrence

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

A flow cytometric study of non-small cell lung cancer classified as T1N0

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

The distribution of secondary growths in cancer of the breast. 1889

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Relation of neovascularisation to metastasis of non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Angiogenesis as a predictor of survival after surgical resection for stage I non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Angiogenesis as a Prognostic Indicator of Survival in Non-Small-Cell Lung Carcinoma: a Prospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Tumor angiogenesis as a prognostic marker in operable non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Vascular endothelial growth factor expression in non-small-cell lung cancer: prognostic significance in squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Significance of plasminogen activator inhibitor 2 as a prognostic marker in primary lung cancer: association of decreased plasminogen activator inhibitor 2 with lymph node metastasis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Elevated plasma levels of urokinase plasminogen activator receptor in non-small cell lung cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Predicting the sites of metastases from lung cancer using molecular biologic markers.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Immunohistochemical study of cathepsin B. Prognostic significance in human lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Expression of Blood-Group Antigen A — A Favorable Prognostic Factor in Non-Small-Cell Lung Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Correlation of Expression of H/LeY/LeBAntigens with Survival in Patients with Carcinoma of the Lung

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Correlation of expression of ABH blood group carbohydrate antigens with metastatic potential in human lung carcinomas

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Immunostains for blood group antigens lack prognostic significance in T1 lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Epigenetics: regulation through repression

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Microsatellite alterations in serum DNA of head and neck cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Alterations in DNA Methylation: A Fundamental Aspect of Neoplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Number of CpG islands and genes in human and mouse

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

An alternative promoter in the mouse major histocompatibility complex class II I-Abeta gene: implications for the origin of CpG islands

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

A bird's eye view of global methylation

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Identification of CpG islands hypermethylated in human lung cancer by the arbitrarily primed-PCR method

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Distinct hypermethylation patterns occur at altered chromosome loci in human lung and colon cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

CpG island methylator phenotypes in aging and cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Correlation between methylation status of the p16/CDKN2 gene and the expression of p16 and Rb proteins in primary non-small cell lung cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Hypermethylation of the death-associated protein (DAP) kinase promoter and aggressiveness in stage I non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Adenomatous polyposis coli gene promoter hypermethylation in non-small cell lung cancer is associated with survival.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Promoter methylation of DAP-kinase: association with advanced stage in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

E-cadherin expression is commonly downregulated by CpG island hypermethylation in esophageal carcinoma cells

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Aberrant methylation of p16(INK4a) is an early event in lung cancer and a potential biomarker for early diagnosis

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Hypermethylated APC DNA in plasma and prognosis of patients with esophageal adenocarcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Detection of occult micrometastases in non-small cell lung carcinoma by reverse transcriptase-polymerase chain reaction

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Immunohistochemical assessment of individual tumor cells in lymph nodes of patients with non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Frequency and prognostic significance of isolated tumour cells in bone marrow of patients with non-small-cell lung cancer without overt metastases

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Relationship between early recurrence and micrometastases in the lymph nodes of patients with stage I non-small-cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Micrometastatic P53-positive cells in the lymph nodes of non-small-cell lung cancer: prognostic significance

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Detection of occult bone marrow micrometastases in patients with operable lung carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Detection of micrometastases in histologically negative lymph nodes in esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

The prognostic significance of lymph node micrometastasis in patients with esophageal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Expression of Bax, a pro-apoptotic member of the Bcl-2 family, in esophageal squamous cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

Mutations of p53 in Barrett's esophagus and Barrett's cancer: a prospective study of ninety-eight cases.

1 reference

https://api.crossref.org/works/10.1016%2FS0039-6109%2802%2900024-5

7 January 2021

10.1016/S0039-6109(02)00024-5

Identifiers

DOI

1 reference

5 August 2017

1 reference